Specialty Pharmaceuticals for Hyperlipidemia — Impact on Insurance Premiums
Authors:
- 22 October 2015
- journal article
- editorial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 373 (17) , 1591-1593
Abstract
The Food and Drug Administration (FDA) recently approved alirocumab and evolocumab, PCSK9 inhibitors, for the treatment of hyperlipidemia. These novel biologic agents offer the promise of reductions in blood cholesterol levels. Specifically, the FDA approved alirocumab as an “adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, who require additional lowering of LDL [low-density lipoprotein]-cholesterol.”1 This broad indication sets the practice of cardiology on a collision course with specialty pharmaceutical pricing models that were previously reserved for drugs that benefited relatively limited patient populations.Keywords
This publication has 3 references indexed in Scilit:
- The Impact Of Specialty Pharmaceuticals As Drivers Of Health Care CostsHealth Affairs, 2014
- Specialty Medications: Traditional And Novel Tools Can Address Rising Spending On These Costly DrugsHealth Affairs, 2014
- Proposed ‘Grant-And-Access’ Program With Price Caps Could Stimulate Development Of Drugs For Very Rare DiseasesHealth Affairs, 2012